Thymosin Alpha-1 Research Peptide

Thymosin Alpha-1 came out of a long hunt for the hormones of the thymus. In the mid-1960s the group of Klein, Goldstein and White prepared thymosin fraction 5 from calf thymus, a crude mixture of peptides between roughly 1 and 15 kDa. In 1977 Allan Goldstein’s team pulled one component out of that mixture, a heat-stable, highly acidic polypeptide of 28 residues, worked out its complete sequence and named it thymosin α1 (Learn more).

The “thymus” label turned out to be only part of the story. Thymosin Alpha-1 is the opening section of a bigger protein, prothymosin alpha, which is involved in chromatin remodelling and is made well beyond the thymus. The free peptide has been detected in the cytosol of a range of mammalian tissues, so researchers now treat it as a naturally occurring fragment with possible roles of its own, not just an artefact of the original extraction.

A large share of modern work focuses on dendritic cells, the sentinels that sample microbes and decide what kind of T-cell response follows. A widely cited study in the journal Blood used dendritic cells exposed to the mould Aspergillus fumigatus. Thymosin Alpha-1 drove those cells to mature and release interleukin-12, acting through the p38 MAP kinase and NF-κB pathways and relying on MyD88, the adaptor protein that most toll-like receptors signal through.

The animal results gave that cell work its weight. In mice, the synthetic peptide strengthened T-helper 1 antifungal immunity, accelerated the recovery of myeloid cells, and protected highly susceptible animals that had received haematopoietic transplants from aspergillosis. The authors framed it as a candidate adjuvant able to coordinate innate and adaptive responses, and dendritic-cell maturation assays remain a common entry point for new Thymosin Alpha-1 projects.

Thymalfasin is the generic drug name for synthetic Thymosin Alpha-1, and it is sold as Zadaxin by SciClone Pharmaceuticals. China approved it for hepatitis B in 1995, and it has since been registered in around three dozen countries, from Argentina to Vietnam, for uses that have included chronic hepatitis B and C and, in some markets, support for vaccine responses.

The picture in the US and UK is different. Thymalfasin has never been approved by the US Food and Drug Administration; it received an FDA orphan-drug designation in 2006 for stage IIb to IV malignant melanoma, but a designation is not an approval. Nor does it hold a UK marketing authorisation. The material Crown Peptides supplies shares the same sequence but is research-grade peptide made for laboratory work, and it is not Zadaxin.

Severe sepsis can leave the immune system depleted after the first inflammatory surge, so Thymosin Alpha-1 has long been examined in critical-care research. The biggest test so far, the TESTS trial, randomised 1,106 adults with sepsis across 22 hospitals in China between 2016 and 2020, and its results appeared in the BMJ in 2025 (Learn more).

The headline was clear. Death from any cause by day 28 occurred in 23.4% of the thymosin α1 group and 24.1% of the placebo group, a difference that was not statistically significant, and no secondary or safety outcome differed either. Pre-specified subgroups hinted that age and diabetes might change the response, findings that still need confirming. For laboratory scientists, the trial is a reminder that striking immune-cell data do not automatically carry through to the clinic, and it has sharpened interest in exactly which immune states the peptide modulates.

In plain water the peptide has no preferred shape: circular dichroism and NMR studies show it behaving as a flexible, disordered chain. Give it a membrane-like environment and it changes. With phospholipid vesicles, detergent micelles or zinc ions it becomes partly ordered, and in a mixture of water and trifluoroethanol an 800 MHz NMR study found a stable alpha-helix running from residue 14 to residue 26, with a twisted, turn-rich region across the first twelve.

A later study in sodium dodecyl sulphate micelles reported that the N-terminal end pushes into the micelle as the peptide folds, giving a helix with a break around residues 9 to 14. Because no single dedicated receptor has yet been identified, these membrane experiments are one of the main ways researchers picture how Thymosin Alpha-1 first meets a cell.